PRIMA BIOMED

Australian biotechnology company Prima BioMed Ltd is one of the world's leaders when it comes to cancer treatment. We focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of what we call the cutting edge of the fight against cancer.

Product Development The company has 2 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. >>	Scientific Research Prima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies. >>	Clinical Trial CVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells. >>	Latest News 13 June 2013 Prima BioMed Ltd - Completion of Entitlement Offer >> 13 June 2013 Investor Update Edition 10 >> 23 May 2013 Ärzteblatt Sachsen: Die Autologe Immuntherapie des Ovarialkarzinoms – Eine neue Chance? // Autologous immunotherapy forovarian carcinoma – A new chance? >> Read more news >> Press and Video Webcasts >> Manufacturing of CVac >> Interview Marc Voigt (D) >> Interview Matt Lehman >> Video about CVac™ >> Channel 7 News >> Channel 10 News >> Channel 7 News >>
Connect with Prima Receive email updates and follow us on Facebook, Twitter and on LinkedIn: